Key takeaways
- 400–500 Estimated UK Dravet syndrome patient population · Dravet UK Society data 2023
- 75% SCN1A pathogenic variant confirmation rate in clinical Dravet syndrome; de novo in 80–90% of cases · NHS GMS epilepsy gene panel data
- 2–18% Lifetime SUDEP risk range in Dravet syndrome, depending on seizure control · NICE NG217 epilepsy guideline 2022
Free NHS GMS SCN1A testing confirms 75% of clinical Dravet syndrome diagnoses in the UK, feeding a NICE-sequenced treatment algorithm (cannabidiol first, then fenfluramine) delivered across 25 dedicated NHS paediatric epilepsy centres.
Dravet syndrome is a severe, genetically defined developmental and epileptic encephalopathy, with de novo SCN1A pathogenic variants confirmed in an estimated 80–90% of UK cases (no family history) and clinical molecular confirmation running at roughly 75%. An estimated 400–500 patients are living with Dravet syndrome in the UK. The NHS Genomic Medicine Service offers SCN1A testing free of charge as part of an epilepsy gene panel to any patient presenting with febrile-seizure-onset epilepsy, with standard turnaround of 8–16 weeks and a fast-track route of under 2 weeks for infantile encephalopathy presentations — placing the UK among the highest molecular-confirmation-rate countries for Dravet syndrome globally.
Management runs on a NICE-defined sequence rather than physician discretion: valproate and clobazam first, with sodium-channel blockers contraindicated and documented, then cannabidiol (Epidiolex, NICE TA614, 2019) added and reassessed at 12 weeks, then fenfluramine (Fintepla, NICE TA887, 2022) added for inadequate responders. Both agents require prescription through one of 25 NHS Highly Specialised Service paediatric epilepsy centres, and fenfluramine carries a mandatory cardiac monitoring obligation — the Fintepla Cardiac Monitoring Scheme (FCMS). SUDEP risk (2–18% lifetime, depending on seizure control) is a structural feature of NHS Dravet management: NICE NG217 (2022) mandates a SUDEP risk discussion at every epilepsy review, and the NHS 'SUDEP and Seizure Safety Checklist' is used at all UK epilepsy centres.
NICE-recommended Dravet syndrome therapies — United Kingdom, 2026
| Drug (Brand / INN) | Class | Company | NICE Status | Sequence Position | Monitoring Requirement |
|---|---|---|---|---|---|
| Epidiolex (cannabidiol) | Oral CBD | Jazz Pharmaceuticals | NICE TA614 — recommended (2019) | Added to valproate + clobazam; reassessed at 12 weeks | Standard epilepsy follow-up |
| Fintepla (fenfluramine) | Serotonin-releasing agent | UCB | NICE TA887 — recommended (2022) | Second-line after inadequate CBD response | Mandatory cardiac monitoring (FCMS) |
Sources: NICE TA614 (2019) and TA887 (2022) commissioning documents; NHS England Highly Specialised Service specification; NHS GMS epilepsy gene panel specifications; Dravet UK Society data 2023.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How does the NHS GMS free SCN1A gene panel shape UK Dravet syndrome diagnosis and molecular confirmation rates? • SCN1A gene panel access and turnaround • molecular confirmation rate vs clinical diagnosis • de novo mutation prevalence • fast-track pathway for infantile encephalopathy presentations
- What does the NICE TA614/TA887 cannabidiol-then-fenfluramine sequence mean for positioning a new Dravet therapy against the UK background regimen? • NICE-defined treatment algorithm and reassessment points • cardiac monitoring obligation for fenfluramine • the evidence bar a new agent must clear over CBD+fenfluramine background
- How does SUDEP risk and the NHS epilepsy monitoring programme factor into UK Dravet syndrome commercial and medical-affairs planning? • SUDEP risk range and NICE NG217 monitoring mandate • the NHS Seizure Safety Checklist • Genomics England 100,000 Genomes Project Dravet cohort as a long-term outcomes resource
What's inside
-
1 · Disease Biology & SCN1A Genetics 4 pp
- How de novo SCN1A pathogenic variants, confirmed in 80-90% of UK cases with no family history, define Dravet syndrome as a genetically determined encephalopathy
- Why clinical molecular confirmation of SCN1A runs at roughly 75% despite the high de novo mutation rate seen in UK Dravet cases
-
2 · UK Epidemiology — 400–500 Patients, 75% SCN1A Confirmation via Free NHS GMS Testing 5 pp
- How the NHS Genomic Medicine Service's free SCN1A epilepsy gene panel, with 8-16 week standard turnaround, places the UK among the highest confirmation-rate countries globally
- The under-2-week fast-track SCN1A testing route for infantile encephalopathy presentations against an estimated 400-500 UK Dravet patients
-
3 · NICE TA614/TA887 Treatment Algorithm — Cannabidiol First, Fenfluramine Second 5 pp
- The NICE-defined sequence: valproate and clobazam first, cannabidiol (Epidiolex, TA614) added and reassessed at 12 weeks, then fenfluramine (Fintepla, TA887) for inadequate responders
- Why sodium-channel blockers are contraindicated and documented before any NICE-recommended Dravet agent is prescribed
-
4 · NHS Paediatric Epilepsy Centre Network — 25 Designated HSS Centres 4 pp
- Why both cannabidiol and fenfluramine require prescription through one of only 25 NHS Highly Specialised Service paediatric epilepsy centres
- How the Fintepla Cardiac Monitoring Scheme (FCMS) mandatory cardiac monitoring obligation is administered across this 25-centre network
-
5 · SUDEP Risk & NHS Monitoring — 2–18% Lifetime Risk Under NICE NG217 4 pp
- Why lifetime SUDEP risk in Dravet syndrome ranges from 2% to 18% depending on seizure control, and how NICE NG217 mandates a risk discussion at every review
- How the NHS 'SUDEP and Seizure Safety Checklist,' used at all UK epilepsy centres, operationalises NG217's monitoring requirement
-
6 · Pipeline & Unmet Need Beyond CBD + Fenfluramine 3 pp
- The evidence bar a new Dravet therapy must clear against the NICE-established cannabidiol-plus-fenfluramine background regimen
- How the Genomics England 100,000 Genomes Project Dravet cohort offers a long-term outcomes resource for evaluating pipeline agents
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx UK Dravet Syndrome Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the UK Dravet syndrome patient population. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, geography, and epidemiological focus.
- 2. Scoping callAXLRx analyst confirms subpopulation scope, data sources, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
UK Dravet syndrome disease landscape is built from primary NHS and NICE sources: NHS Genomic Medicine Service gene panel specifications, NICE technology appraisal documentation, and NHS England Highly Specialised Service commissioning specifications, together with UK patient-organisation and national research-cohort data, not secondary summaries or unverified estimates.
Key sources: NICE TA614 (2019) and TA887 (2022) commissioning documents; NHS England HSS specification; NHS GMS epilepsy gene panel specifications; NICE NG217 epilepsy guideline (2022); Dravet UK Society data 2023; Genomics England 100,000 Genomes Project Dravet cohort; SUDEP Action UK data.
- UK Dravet population estimate verified against Dravet UK Society data 2023
- NICE treatment algorithm verified against NICE TA614 (2019) and TA887 (2022) commissioning documents
- SCN1A gene panel access and turnaround verified against NHS GMS epilepsy gene panel specifications
- SUDEP risk and monitoring mandate verified against NICE NG217 epilepsy guideline 2022 and SUDEP Action UK data
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model, and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only — NHS Genomic Medicine Service specifications, NICE technology appraisals, NHS England commissioning documentation, and UK patient-organisation and national research-cohort data. No secondary summaries or market-research reports. Every factual claim is independently verified before inclusion.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparators, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, including additional payer markets, pipeline agent profiles, or country-specific deep-dives, can be added to any standard assessment.